Collegium Pharmaceutical Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 874.31, 900.72, 825.36, 874.47, 950.1 ], "ebit_estimate": [ 465.42, 411.59, 413.7, 482.2, 506 ], "ebitda_estimate": [ 486.3, 513.4, 492.45, 448.7, 472.8 ], "net_income_estimate": [ 304.02, 294.79, 259.07, 291, 308.6 ], "per_share_eps_estimate": [ 2.66, 3.73, 4.1, null, null ], "eps_nri_estimate": [ 7.72, 7.61, 6.68, 7.24, 7.7 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 10.79, 15.4, null, null, null ], "pretax_income_estimate": [ 379.19, 367.12, 372.53, 420.25, 444.2 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ 5.2, 7, null, null, null ], "roe_estimate": [ 24.3, 24.1, null, null, null ], "gross_margin_estimate": [ 88.45, 88.08, 88.77, 89.15, 89.15 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 13.24, 9.44, 8.59, null, null ], "long_term_growth_rate_mean": -3.25, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 34, "future_eps_nri_estimate_growth": -3.25, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -4.08, "future_ebitda_estimate_growth": 2.59, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -3.55, "future_pretax_income_estimate_growth": -1.73, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.29, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 201.05, 234.99, 244.97, 210.62, 223.02, 231.97, 239.45 ], "ebit_estimate": [ 91.15, 109.28, 117.44, 77.74, 87.31, 95.17, 100.2 ], "ebitda_estimate": [ 110.83, 135.14, 137.6, 119.86, 131.32, 139.57, 145.29 ], "net_income_estimate": [ 68.62, 81.51, 86.28, 63.19, 70.74, 77.15, 81.5 ], "per_share_eps_estimate": [ 0.51, 0.82, 0.95, 0.73, 0.89, 1, 1.1 ], "eps_nri_estimate": [ 1.72, 2.08, 2.21, 1.71, 1.9, 2.08, 2.2 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 8.46, 9.51, 10.62, 11.61, 12.7, 13.88, 15.16 ], "pretax_income_estimate": [ 81.91, 102.88, 108.03, 65.89, 75.15, 83.57, 89.43 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ 1, 1.7, 1.9, 1.4, 1.7, 1.9, 2.1 ], "roe_estimate": [ 6, 8.6, 8.8, 6.2, 7, 7.1, 7.2 ], "gross_margin_estimate": [ 88.13, 88.13, 88.13, 87, 87, 86.95, 86.95 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 11.7, 10.39, 9.87, 9.47, null, null, null ], "long_term_growth_rate_mean": -3.25, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 34, "future_eps_nri_estimate_growth": -3.25, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -4.08, "future_ebitda_estimate_growth": 2.59, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -3.55, "future_pretax_income_estimate_growth": -1.73, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.29, "future_operating_cash_flow_per_share_estimate_growth": null }